Physician profile
Cecilia Choi
NPI 1558562371
$4,414.84
in general payments reported to CMS, 2019-2025
33 companies · $3,023 in 2025
The $3,023 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.33 · 2022: $295 · 2023: $293 · 2024: $780 · 2025: $3,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624 · Long Term Medical Supply Or Device Loan: $1,097 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.16 |
| Long Term Medical Supply Or Device Loan | $1,096.70 |
| Education | $374.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,354.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $428.28 | 2022-2025 | Imfinzi, Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $422.49 | 2022-2025 | Opdivo, Opdualag |
| Pfizer INC. | $297.01 | 2022-2025 | |
| Caris Mpi, INC. | $228.05 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $220.87 | 2022-2024 | Xtandi |
| Janssen Biotech, INC. | $131.19 | 2022-2025 | Erleada |
| Eisai INC. | $128.29 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $119.00 | 2024-2025 | |
| Beone Medicines USA, INC. | $102.79 | 2025 | Tevimbra |
| Seagen INC. | $99.00 | 2025 | |
| Tempus Ai, INC | $92.26 | 2025 | Xt Cdx |
| Regeneron Healthcare Solutions, INC. | $86.32 | 2024-2025 | Libtayo |
| Array Biopharma INC | $81.71 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.75 | 2023-2025 | Gilotrif |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $54.42 | 2024-2025 | |
| Gilead Sciences, INC. | $51.59 | 2024-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $50.09 | 2025 | Ninlaro |
| Genentech USA, INC. | $44.02 | 2020-2025 | Tecentriq |
| Sumitomo Pharma America, INC. | $42.64 | 2025 | Orgovyx |
| Emd Serono, INC. | $40.80 | 2025 | |
| Merck Sharp & Dohme LLC | $31.02 | 2025 | Keytruda |
| Deciphera Pharmaceuticals INC. | $29.25 | 2022 | |
| Abbvie INC. | $26.06 | 2025 | |
| Foundation Medicine, INC. | $24.05 | 2022 | |
| Blueprint Medicines Corporation | $23.06 | 2024 | Ayvakit |
| Novocure INC. | $22.68 | 2024 | Optune |
| Taiho Oncology, INC. | $22.34 | 2024 | |
| Stemline Therapeutics INC. | $22.08 | 2025 | Orserdu |
| Urogen Pharma, INC. | $21.69 | 2025 | |
| Springworks Therapeutics, INC. | $21.48 | 2024 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $20.90 | 2022 | |
| Daiichi Sankyo INC. | $18.37 | 2025 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecilia Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.